In summary, non-pathogenic germline MSH2 variants and MSH2 promotor methylation was shown to be associated with the extent of neurofibroma manifestation in NF1 patients (without microdeletions) indicating an influence on MMR activity. The gene discussed is MSH2; the disease is plexiform neurofibroma.